ArticleLeukemia2021
A highly heterogeneous mutational pattern in POEMS syndrome.
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2026Review
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
- Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression.Nature genetics · 2025Article
- LncRNA NR2F1-AS1 is involved in osteogenic differentiation in fracture healing via miR-423-5p.Cytotechnology · 2025Article
- Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.Genomics, proteomics & bioinformatics · 2025Article
- Pig jejunal single-cell RNA landscapes revealing breed-specific immunology differentiation at various domestication stages.Frontiers in immunology · 2025Article
- POEMS syndrome with undetectable M-protein: a case report and literature review.Diagnostic pathology · 2024Review
- Innate immune pathway modulator screen identifies STING pathway activation as a strategy to inhibit multiple families of arbo and respiratory viruses.Cell reports. Medicine · 2023Article
- Triple-negative Thrombocythemia and Subsequent Acute Lymphoblastic Leukemia with Additional Somatic Mutations.Internal medicine (Tokyo, Japan) · 2023Article
- Homeobox A3 and KDM6A cooperate in transcriptional control of aerobic glycolysis and glioblastoma progression.Neuro-oncology · 2023Article
- Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses.bioRxiv : the preprint server for biology · 2023Article
- A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer.Frontiers in immunology · 2023Article
- Bayesian model and selection signature analyses reveal risk factors for canine atopic dermatitis.Communications biology · 2022Article
- Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis.JCI insight · 2022Article
- Update on the POEMS syndrome.Blood research · 2022Review
- Formins in Human Disease.Cells · 2021Review
- POEMS syndrome remains a mystery after 40 years.Leukemia · 2021Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POEMS syndrome is a rare plasma cell dyscrasia. Little is known about its pathogenesis and genetic features. We analyzed the mutational features of purified bone marrow plasma cells from 42 patients newly diagnosed with POEMS syndrome using a two-step strategy. Whole exome sequencing of ten patients showed a total of 170 somatic mutations in exonic regions and splicing sites, with paired peripheral blood mononuclear cells as a control. Three significantly mutated genes-LILRB1 (10%), HEATR9 (20%), and FMNL2 (10%)-and eight mutated known driver genes (MYD88, NFKB2, CHD4, SH2B3, POLE, STAT3, CHD3, and CUX1) were identified. Target region sequencing of 77 genes were then analyzed to validate the mutations in an additional 32 patients. A total of 32 mutated genes were identified, and genes recurrently mutated in more than three patients included CUX1 (19%), DNAH5 (16%), USH2A (16%), KMT2D (16%), and RYR1 (12%). Driver genes of multiple myeloma (BIRC3, LRP1B, KDM6A, and ATM) and eleven genes reported in light-chain amyloidosis were also identified in target region sequencing. Notably, VEGFA mutations were detected in one patient. Our study revealed heterogeneous genomic profiles of bone marrow plasma cells in POEMS syndrome, which might share some similarity to that of other plasma cell diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.